1.646.889.1200|info@lifescipublicrelations.com

Krystal Gains on Early Data for Topical Gene Therapy in Skin Blistering Disease

//Krystal Gains on Early Data for Topical Gene Therapy in Skin Blistering Disease

Krystal Gains on Early Data for Topical Gene Therapy in Skin Blistering Disease

Krystal Biotech Inc. (NASDAQ:KRYS) added $4.32 (28%) to $20 on Monday when it reported interim data from the Phase I/II GEM trial showing that topical gene therapy KB103 met all primary efficacy and safety endpoints in two adults with recessive dystrophic epidermolysis bullosa.

By | 2018-10-15T17:06:22-04:00 October 15th, 2018|News|Comments Off on Krystal Gains on Early Data for Topical Gene Therapy in Skin Blistering Disease

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.